INGEST I Pilot Study (INGEST)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03885310 |
Recruitment Status :
Recruiting
First Posted : March 21, 2019
Last Update Posted : March 21, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Esophageal Stricture | Device: GIE Drug Coated Balloon | Not Applicable |
The study is designed to determine the safety and effectiveness of drug coated balloon (DCB) treatments on esophageal stricture.
Up to 30 subjects are planned to be enrolled and treated with the study device at up to 5 clinical sites outside of US. Subjects will be followed up post-treatment to one year and then annually for up to 5 years. The annual follow up after the first year is optional.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Gastrointestinal Drug-Coated Balloon for the Treatment of Symptomatic Recurrent Benign Esophageal Stricture |
Actual Study Start Date : | February 24, 2019 |
Estimated Primary Completion Date : | December 2020 |
Estimated Study Completion Date : | December 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: DCB Treatment
Stricture patients treated by DCB
|
Device: GIE Drug Coated Balloon
The GIE DCB is a balloon catheter with a 3 stage inflatable balloon coated with a proprietary coating containing the drug and carriers. |
- Incident of serious balloon dilation-related complications [ Time Frame: 30 days ]Adverse events such as perforation, bleeding requiring intervention, severe pain during swallowing, infection requiring hospitalization or IV antibiotics, dysphagia requiring re-intervention at determined by the attending physician
- Numbers of additional esophageal dilation procedures [ Time Frame: 30 days, 3 months, 6 months, and 12 months ]Repeat stricture treatments
- Time to first dysphagia symptom recurrence [ Time Frame: 30 days, 3 months, 6 months, and 12 months ]Ogilvie Dysphagia Score will be used to assess subject's dysphagia symptom changes at follow-ups. The date of the first reported occurrence of dysphagia symptom will be used to derive the time to first dysphagia symptom recurrence.
- Improvement in dysphagia score [ Time Frame: 30 days, 3 months, 6 months, and 12 months ]Ogilvie Dysphagia Score will be used to assess subject's dysphagia symptom changes at follow-ups. The scores at each follow-up will be compared to the score at baseline.
- Esophageal stricture diameter [ Time Frame: 30 days, 3 months, 6 months, and 12 months ]Endoscopy and esophagography will be conducted to measure the internal caliber of the esophagus. Results will be reported in millimeters.
- Technical success [ Time Frame: Time of procedure ]Successful delivery of the drug coated balloon to the target stricture, balloon inflation to the desired pressure, balloon deflation and withdraw without device malfunction.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 18 and ≤ 80 years.
- Benign esophageal stricture with diameter less than 10 mm (barium esophagram).
- Dysphagia score of 2 to 4 (Ogilvie Dysphagia Score).
- Recurrent stricture after at least 2 previous balloon/bougie dilation or stricturotomy sessions.
- Stricture total length ≤ 7 cm. Tandem or adjacent strictures are allowed if the strictures are caused by the same underlining disease.
- Ability to undergo periodic endoscopic follow-up.
- Voluntary participation and provided written informed consent.
Exclusion Criteria:
- Pregnancy or breastfeeding or plan to get pregnant in next 12 months.
- Contraindication to endoscopy, anesthesia or deep sedation.
- Benign esophageal stricture due to extrinsic esophageal compression.
- Currently required chest radiation therapy.
- Malignant esophageal stricture.
- Stricture total length > 7 cm or esophageal strictures at multiple locations where the total stricture length exceeds 7 cm
- Dysphagia related to primary motility disorders, such as achalasia, diffused esophageal spasm, ineffective esophageal motility (IEM), hypertensive lower esophageal sphincter, etc.
- Active erosive esophagitis.
- Present esophageal ulceration, perforation, leak, fistula, or varices.
- Concurrent gastric and/or duodenal obstruction.
- Active systemic infection.
- Allergy to paclitaxel or any components of the delivery system.
- Severe coagulation disorders or current use of anticoagulant for comorbidities.
- Chronic steroid use for any medical conditions unless subject is willing to undergo a 4-week washout and discontinue steroid use.
- Received steroid injections into target stricture in the last 4 weeks
- Intolerant to proton pump inhibitors.
- Life expectancy of less than 12 months.
- Unwilling or unable to comply with the follow-up study requirements.
- Lacking capacity to provide informed consent.
- Concurrent medical condition that would affect the investigator's ability to evaluate the patient's condition or could compromise patient safety, such as recent myocardial infarction, severe pulmonary disease, bleeding diathesis, large thoracic aneurysm, recent laparotomy, pharyngeal or cervical deformity, etc.
- Currently participation in another pre-market drug or medical device clinical study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03885310
Contact: Peter J Barnett, MS | 763-219-8902 | barnettp@giemedical.com |
Paraguay | |
Adventista Hospital | Recruiting |
Asunción, Paraguay | |
Contact: Carlos A Cetraro 0981 524 485 cetraroca@gmail.com |
Principal Investigator: | Kenneth Wang, MD | Mayo Clinic |
Responsible Party: | GIE Medical |
ClinicalTrials.gov Identifier: | NCT03885310 |
Other Study ID Numbers: |
PR2001 |
First Posted: | March 21, 2019 Key Record Dates |
Last Update Posted: | March 21, 2019 |
Last Verified: | March 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Esophageal Stenosis Constriction, Pathologic Pathological Conditions, Anatomical |
Esophageal Diseases Gastrointestinal Diseases Digestive System Diseases |